DarioHealth announced preliminary unaudited revenue results for the Q4. Q4 revenues were driven by B2B channel growth that surpassed the managed decline of the B2C channel due to the Company’s strategic shift in resources. In addition, the Company reduced its operating loss by more than 30% compared to the Q3, and by more than 50% compared to the Q4 of FY21. Erez Raphael, CEO of Dario, said, "Based on our expected preliminary results, we delivered higher revenues on lower spend, demonstrating that our strategy of moving from B2C to B2B sales channels is working and is the value maximizing path for the Company. We believe that the expected 2022 results are especially exciting because B2B revenue represents the majority of our revenue for the first time. The growth of the B2B business has resulted in an overall significant improvement in the financial profile of the Company. In 2023, we anticipate the continued growth of our B2B revenue as we execute on our strategic plan."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DRIO:
- DarioHealth Announces Preliminary Fourth Quarter and Full Year 2022 Operating Results
- DarioHealth participates in a conference call with Lake Street
- DarioHealth achieves goal of 100 business-to-business contracts in 2022
- DarioHealth announces new partnership with ECES
- DarioHealth: Study demonstrates effectiveness of musculoskeletal solution